Ovoca Bio (CDI) (OVB)

Sector:

Pharma and Biotech

 1.15p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 1.92p
  • 52 Week Low: 0.68p
  • Currency: UK Pounds
  • Shares Issued: 88.46m
  • Volume: 0
  • Market Cap: £1.02m

Key dates

Dividend  
Latest XD Date (Interim) n/a
Latest Pay Date (Interim) n/a
   
Meetings  
AGM 18-Dec-2024
EGM 16-Feb-2021
GMs n/a
   
Announcements  
Trading announcement 07-Dec-2010
IMSs n/a
Drilling Report 03-Feb-2012
   
Results  
Final results 26-Jun-2025
Interim results 28-Sep-2023
Q1 Results n/a
Q2 Results n/a
Q3 Results n/a
Q4 Results n/a
Annual Report 26-Jun-2025
   
Year End n/a

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Ovoca Bio (CDI) Market Data

Currency UK Pounds
Share Price 1.15p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 1.92p
52 Week Low 0.68p
Volume 0
Shares Issued 88.46m
Market Cap £1.02m

Ovoca Bio (CDI) Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
0.16% above the market average0.16% above the market average0.16% above the market average0.16% above the market average0.16% above the market average
26.83% above the sector average26.83% above the sector average26.83% above the sector average26.83% above the sector average26.83% above the sector average
Value
0.16% above the market average0.16% above the market average0.16% above the market average0.16% above the market average0.16% above the market average
26.83% above the sector average26.83% above the sector average26.83% above the sector average26.83% above the sector average26.83% above the sector average
Income Not Available
Growth Not Available

Ovoca Bio (CDI) Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

Ovoca Bio (CDI) Key Personnel

CEO Timothy McCutcheon

Top of Page